Intrinsic Value of S&P & Nasdaq Contact Us

Roche Holding AG RHHBF OTC

Other OTC • Healthcare • Drug Manufacturers - General • CH • USD

SharesGrow Score
67/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Roche Holding AG (RHHBF) generated $11.24B in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $2.07B, free cash flow was $9.17B.

Free cash flow margin was 30% of revenue. Cash conversion ratio was 2.05x, indicating earnings are backed by cash.

The company returned $654.31M in dividends and $483.23M in share buybacks to shareholders during the quarter.

Criteria supported by this page:

  • HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
  • MOAT (94/100, Pass) — $9.17B (30% margin) supports a durable competitive advantage
  • INCOME (85/100) — Cash conversion ratio was 2.05x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 67/100 with 4/7 criteria passed.

SharesGrow 7-Criteria Score
67/100
SG Score
View full scorecard →
VALUE
60/100
Price-to-Earnings & upside
→ Valuation
FUTURE
20/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
94/100
Proven by this page
~
GROWTH
40/100
→ Income
INCOME
85/100
→ Income
Roche Holding AG Cash Flow History
Metric TTM Q4 FY2025 Q2 FY2025 Q4 FY2024 Q2 FY2024
Operating Cash Flow $34.88B$11.24B$3.55B$12.18B$7.91B
Capital Expenditure $-7.92B$-2.07B$-840M$-3.29B$-1.72B
Free Cash Flow $26.96B$9.17B$2.71B$8.9B$6.19B
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message